patients to be intermediate between groups of 18 healthy controls and 10 schizophrenia patients, suggesting that impaired alpha ERD may present a possible risk indicator for the development of schizophrenia. The present findings support this notion in that all three patients who later developed schizophrenia showed even more pronounced reductions of alpha ERD than the entire group of CHR patients. Koh et al. did not specify alpha ERD reductions for three individuals who made a transition to psychosis within a two-year follow-up period.
